These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1381438)

  • 61. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
    Tisdale M; Kemp SD; Parry NR; Larder BA
    Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effect of perinatal short-course zidovudine on the clinical and virological manifestations of HIV-1 subtype E infection in infants.
    Sutthent R; Chokephaibulkit K; Piyasujabul D; Vanprapa N; Roogpisuthipong A; Chaisilwatana P
    J Clin Virol; 2002 Jul; 25(1):47-56. PubMed ID: 12126721
    [TBL] [Abstract][Full Text] [Related]  

  • 63. HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. The AIDS Clinical Trials Group Study 175 Virology Team.
    Rey D; Hughes M; Pi JT; Winters M; Merigan TC; Katzenstein DA
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Mar; 17(3):203-8. PubMed ID: 9495218
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).
    Dis Markers; 1990; 8(3):163-4. PubMed ID: 1703061
    [No Abstract]   [Full Text] [Related]  

  • 65. Emergence of mutant HIV reverse transcriptase conferring resistance to AZT.
    Richman DD
    J Enzyme Inhib; 1992; 6(1):55-64. PubMed ID: 1285303
    [No Abstract]   [Full Text] [Related]  

  • 66. Rapid development of genotypic resistance to lamivudine when combined with zidovudine in pregnancy.
    Clarke JR; Braganza R; Mirza A; Stainsby C; Ait-Khaled M; Wright A; Lyall H; Parker D; McClure MO; Weber JN; Taylor GP
    J Med Virol; 1999 Nov; 59(3):364-8. PubMed ID: 10502270
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Use of self-sustained sequence replication amplification reaction to analyze and detect mutations in zidovudine-resistant human immunodeficiency virus.
    Gingeras TR; Prodanovich P; Latimer T; Guatelli JC; Richman DD; Barringer KJ
    J Infect Dis; 1991 Dec; 164(6):1066-74. PubMed ID: 1955709
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients.
    Kuritzkes DR; Quinn JB; Benoit SL; Shugarts DL; Griffin A; Bakhtiari M; Poticha D; Eron JJ; Fallon MA; Rubin M
    AIDS; 1996 Aug; 10(9):975-81. PubMed ID: 8853730
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
    Ross L; Johnson M; Graham N; Shaefer M; St Clair M
    J Hum Virol; 1999; 2(5):290-5. PubMed ID: 10551735
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
    Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
    AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
    Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM
    J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Analysis of HIV-1 reverse transcriptase gene mutations in infected children treated with zidovudine.
    Orlandi P; Cancrini C; Scaccia S; Romiti ML; Livadiotti S; Gattinara GC; Angelini F; Cox S; Rossi P
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Nov; 19(3):230-7. PubMed ID: 9803964
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Occurrence of HIV-1 reverse transcriptase gene mutation at codon 215 in HIV-infected infants.
    Kamkamidze G; Sullivan T; Charbonneau T
    J Clin Virol; 2001 Aug; 22(1):143-8. PubMed ID: 11418362
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine.
    Frenkel LM; Wagner LE; Atwood SM; Cummins TJ; Dewhurst S
    J Clin Microbiol; 1995 Feb; 33(2):342-7. PubMed ID: 7714190
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Convergent evolution of reverse transcriptase (RT) genes of human immunodeficiency virus type 1 subtypes E and B following nucleoside analogue RT inhibitor therapies.
    Sato H; Tomita Y; Shibamura K; Shiino T; Miyakuni T; Takebe Y
    J Virol; 2000 Jun; 74(11):5357-62. PubMed ID: 10799614
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A microtitre format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type-1 infected patients treated with zidovudine.
    Kaye S; Loveday C; Tedder RS
    J Med Virol; 1992 Aug; 37(4):241-6. PubMed ID: 1383414
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor.
    Staszewski S; Massari FE; Kober A; Göhler R; Durr S; Anderson KW; Schneider CL; Waterbury JA; Bakshi KK; Taylor VI
    J Infect Dis; 1995 May; 171(5):1159-65. PubMed ID: 7538547
    [TBL] [Abstract][Full Text] [Related]  

  • 78. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.
    Miller V; Ait-Khaled M; Stone C; Griffin P; Mesogiti D; Cutrell A; Harrigan R; Staszewski S; Katlama C; Pearce G; Tisdale M
    AIDS; 2000 Jan; 14(2):163-71. PubMed ID: 10708287
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group.
    Mayers DL; Japour AJ; Arduino JM; Hammer SM; Reichman R; Wagner KF; Chung R; Lane J; Crumpacker CS; McLeod GX
    Antimicrob Agents Chemother; 1994 Feb; 38(2):307-14. PubMed ID: 8192457
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates.
    Kellam P; Larder BA
    Antimicrob Agents Chemother; 1994 Jan; 38(1):23-30. PubMed ID: 8141575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.